Presented at 2023 SITC Meeting – A pre-planned biomarker analysis of patients treated with bemcentinib in combination with KEYTRUDA® (pembrolizumab) yields new understandings- BERGEN, Norway, Nov. 6, 2023 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.